PT  - JOURNAL ARTICLE
AU  - Almdallaleh, Sultan A.
AU  - Alsuwaida, Abdulkareem O.
AU  - Altalhi, Abdulhadi M.
AU  - ALJayar, Dina M.
AU  - Massad, Elzibair E.
AU  - Hamid, Mazaher M.
AU  - Jaganathan, Parameaswari P.
AU  - Al-Hababi, Fadel H.
TI  - Renin-angiotensin-system blockers and IgG antibodies in end-stage renal disease hemodialysis-receiving patients diagnosed with COVID-19 infection
AID  - 10.15537/smj.2023.44.9.20230129
DP  - 2023 Sep 01
TA  - Saudi Medical Journal
PG  - 875--881
VI  - 44
IP  - 9
4099  - http://smj.org.sa/content/44/9/875.short
4100  - http://smj.org.sa/content/44/9/875.full
SO  - Saudi Med J2023 Sep 01; 44
AB  - Objectives: To evaluate the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections among patients receiving in-center hemodialysis (ICHD), the relationship between the IgG antibody levels against the virus and SARS-CoV-2-associated symptoms, hemodialysis adequacy, and the antihypertensives used in order to control blood pressure.Methods: A prospective observational study was carried out at a tertiary care center, King Fahad Kidney Center, Riyadh, Kingdom of Saudi Arabia, between November 2020 and January 2021. A total of 214 ICHD patients with end-stage renal disease (ESRD) were included, and the levels of their anti-SARS-CoV-2 IgG antibodies were assessed after obtaining their informed consent.Results: Our tests indicated that 15% of the patients in the study’s population had detectable SARS-CoV-2 IgG antibodies, with more than half of them (53%) being asymptomatic. We also found that ESRD patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) had higher levels of SARS-CoV-2 IgG antibodies than patients not receiving this group of medications.Conclusion: More studies are required to assess whether patients with a SARS-CoV-2 infection that do not have an indication for being prescribed ACEIs/ARBs would benefit from receiving these medications.